

Regimen Reference Order – BRST – neratinib

ARIA: BRST – [neratinib]

Planned Course: Once daily for 13 cycles (1 cycle = 28 days)

Indication for Use: Breast Cancer; Extended Adjuvant; HER2 Positive, Hormone Receptor Positive

Proceed with treatment if:

- *AST/ALT equal to or less than 5 times the upper limit of normal*
- *Total bilirubin equal to or less than 3 times the upper limit of normal*
- *Proceed regardless of ANC and Platelets*
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – BRST - neratinib

Drug	Dose	CCMB Administration Guideline
Cycle 1		
neratinib	120 mg Days 1-7	Orally once daily with food Swallow whole (Self-administered at home)
	160 mg Days 8-14	
	240 mg Days 15-28	
Cycle 2 and Onwards		
neratinib	240 mg	Orally once daily with food Swallow whole (Self-administered at home)
neratinib (Nerlynx®) available dosage strength: 40 mg tablet Classification: Non-Cytotoxic, Hazardous		

REQUIRED MONITORING

Cardiac Monitoring

- LVEF monitoring is not required at baseline. If clinically indicated, cardiac investigations will occur at prescriber's discretion

Cycles 1 to 3

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders

Cycle 4 and Onwards

Every 3 months or as clinically indicated

- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
loperamide	4 mg	Take as needed for diarrhea (not to exceed 16 mg per day)

INSTRUCTIONS FOR PATIENT

- Ensure patient has received a supply of loperamide
- Patient to inform clinic if they experience 3 or more episodes of diarrhea per day as assessment is required. neratinib dose interruption and dose reduction may be required at physician's discretion
- If patient experiences diarrhea, fluid intake of 2 litres per day should be maintained to avoid dehydration
- neratinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit

ADDITIONAL INFORMATION

- neratinib is used as “extended adjuvant” therapy after completion of 1 year of trastuzumab-based (neo)adjuvant therapy
- neratinib can cause severe diarrhea. Diarrhea is most common during Cycles 1 and 2
- The use of proton pump inhibitors (i.e. omeprazole, pantoprazole, esomeprazole, lansoprazole) needs to be avoided while patients are on neratinib
- H₂-receptor antagonists (such as ranitidine, famotidine) should be avoided with neratinib. If short-term use of a H₂-receptor antagonist cannot be avoided, neratinib must be taken at least 2 hours before the morning dose and 10 hours after the evening dose of the H₂-receptor antagonist
- Antacids should be separated from neratinib dose by at least 3 hours